The Technical Analyst
Select Language :
Auris Medical Holding Ltd [EARS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Auris Medical Holding Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Auris Medical Holding Ltd is listed at the  Exchange

-1.77% CHF3.05

America/New_York / 26 jul 2021 @ 00:00


Auris Medical Holding Ltd: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 4.21 mill
EPS: -1.482
P/E: -2.05
Earnings Date: N/A
SharesOutstanding: 1.384 mill
Avg Daily Volume: 1.894 mill
RATING 2021-07-23
B+
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Buy
P/E: Neutral
Price To Book: Buy
QUARTER GROWTHS
4/212/223/224/221/232/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebitn/an/an/an/an/an/a
Asset n/an/an/an/a
Debtn/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.05 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.35x
Company: PE -2.05 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

CHF 2.80 - 3.29

( +/- 7.98%)
ATR Model: 14 days

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price CHF3.05 (-1.77% )
Volume 0.174 mill
Avg. Vol. 1.894 mill
% of Avg. Vol 9.19 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Auris Medical Holding Ltd

Last 12 Months

Last 12 months chart data with high, low, open and close for Auris Medical Holding Ltd

RSI

Intraday RSI14 chart for Auris Medical Holding Ltd

Last 10 Buy & Sell Signals For EARS

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Auris Medical Holding Ltd

EARS

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Last 10 Buy Signals

Date Signal @
XTZUSDMar 28 - 12:12$1.387
XLMUSDMar 28 - 12:13$0.137
TWTUSDMar 28 - 12:10$1.394
LAMRMar 28 - 12:12$119.31
SBDUSDMar 28 - 12:10$4.75
KUBUSDMar 28 - 12:092.70
EAMar 28 - 12:12$132.80
DXCMMar 28 - 12:12$139.50
EOSUSDMar 28 - 12:13$1.063
ATOMUSDMar 28 - 12:12$12.31

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.